Sean I did think of that, clearly Bayer is the company that would need to lift. The boob that presided over the Monsanto debacle is gone, and the new CEO I believe (Anderson)wants to refocus on the pharmaceutical end of the business. No better way to refocus than to bring a platform drug into the fold. I’ll throw in a six degrees of separation thing too.
Bayer has a partnership with Regeneron pharmaceuticals For Eylea ( Mac degeneration )
George Yancopoulos co president and ceo of Regeneron was a high school classmate of Paul Maddon founder of Progenics, and creator of Pro-140 leronlimab
people talk . Who knows